Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)
| Autor: | Keam, B., Hu, M. I., Subbiah, V., Wirth, L., Schuler, Martin, Mansfield, A. S., Brose, M. S., Curigliano, G., Leboulleux, S., Zhu, V. W., Matos, I., Adkins, D., Baik, C. S., Lopes, G., Godbert, Y., Sarker, D., Zhang, H., Turner, C. D., Taylor, M. H., Lin, C.-C. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: | |
| Popis: | Poster-Abstract |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|